trial
as of 2026-07-01Randomized Double Blind Placebo Control Study in Patients with Schizophrenia
NCTId NCT01602029
at a glance
Phase 2 · Completed
Enrollment 303 (actual)
Sponsored by Pakistan Institute of Living and Learning
Primary completion 2013-06
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
303 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Double
Start
2010-08
Primary completion
2013-06
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Pakistan Institute of Living and LearningLead Sponsor
Stanley Medical Research InstituteCollaborator
Dow University of Health SciencesCollaborator
Abbasi Shaheed HospitalCollaborator
Investigators
1
Prof Imran B Chaudhry, MDPrincipal Investigator
Sites
3 total
Karachi, PakistanKarachi, PakistanKarachi, Pakistan
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
303
Phase
PHASE2
Primary Completion Date
2013-06
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
collaborator
indication
investigator